Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain
View Patent ↗The present invention provides a method of treating fibromyalgia syndrome (FMS), chronic fatigue syndrome (CFS), and pain in an animal subject. The method generally involves administering a therapeutically effective amount of a dual serotonin norepinephrine reuptake inhibitor compound or a pharmaceutically acceptable salt thereof, wherein said dual serotonin norepinephrine reuptake inhibitor compound is characterized by a non-tricyclic structure and an equal or greater inhibition of norepinephrine reuptake than serotonin reuptake. In particular, the use of milnacipran to treat FMS, CFS, and pain is disclosed.
1. A method of treating diabetic peripheral neuropathic pain, the method consisting essentially of orally administering to a patient in need thereof an effective amount of an active ingredient, wherein the active ingredient is at least one compound selected from milnacipran, a pharmaceutically acceptable salt of milnacipran, or a combination thereof, with the proviso that the method excludes administering phenylalanine, tyrosine, or tryptophan.
2. The method of claim 1 , wherein the active ingredient is in a tablet form.
3. The method of claim 1 , wherein the effective amount of the active ingredient is an amount between about 25 mg and about 400 mg per day.
4. The method of claim 1 , wherein the effective amount of the active ingredient is an amount between about 100 mg and about 250 mg per day.
5. The method of claim 1 , wherein the effective amount of the active ingredient is about 100 mg per day.
6. The method of claim 1 , wherein the effective amount of the active ingredient is about 200 mg per day.
7. The method of claim 5 , wherein the effective amount of the active ingredient is administered as a 50 mg dose twice per day.
8. The method of claim 6 , wherein the effective amount of the active ingredient is administered as a 100 mg dose twice per day.
9. The method of claim 8 , wherein the effective amount of the active ingredient is administered as two 50 mg doses in the morning and two 50 mg doses in the evening.